Approved Hospital Formulary
Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:
emtricitabine-rilpivirine-tenofovir alafenamide
emtricitabine-rilpivirine-tenofovir alafenamide
- Non-formulary AIDS Drugs Formulary
- Therapeutic Interchange
Last updated: Dec. 18, 2017
- Black Box Warning: Emtricitabine: Lactic Acidosis, Severe Hepatomegaly
- Black Box Warning: Tenofovir: Lactic acidosis, severe hepatomegaly; hepB co-infection
If ordered for inpatients, dispense individual components.
Inpatients are encouraged to use home supply. Defer initiation to outpatient setting.
Odefsey may be obtained if patient's supply is unavailable.Odefsey contains the tenofovir salt -- tenofovir alafenamide. This dosage form causes less renal impairment over several months exposure or longer than dose the tenofovir disoproxil fumarate (TDF).
As of Aug 2016, the alafenamide salt is not available as a separate drug.ID subcommittee recommended not to substitute the TDF salt for the alatenamide automatically.Odefsey will be non-formulary once the alafenamide salt is available as a separate agent.ORDERED FORMULATION
THERAPEUTIC INTERCHANGE
emtricitabine-rilpivirine-tenofovir alafenamide (Odefsey)
emtricitabine (Emtriva) AND rilpivirine (Edurant) AND tenofovir alafenamide (Vemlidy)
Reviewed: 23 August 2016 (Odefsey), and 27 June 2017 (Odefsey)